<p>Herpes Simplex Virus (HSV) is a common viral infection that causes sores and blisters on the skin, most commonly around the mouth (oral herpes) or genital area (genital herpes). The infection is caused by two types of the virus: HSV-1 and HSV-2. While the virus can remain dormant in the body for extended periods, it can reactivate under certain conditions, leading to recurrent outbreaks. Although HSV is widespread, there is a significant unmet need for more effective antiviral therapies that can reduce the frequency of outbreaks and improve patient quality of life.</p>
<h2><strong>Herpes Simplex Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Herpes Simplex in the 7MM from 2020 to 2034 includes:</p>
<ul>
<li>Total Seroprevalent Cases of HSV</li>
<li>Total Symptomatic Cases of HSV</li>
<li>Total Diagnosed Cases of HSV</li>
<li>Gender-specific Diagnosed Cases of HSV</li>
<li>Total Recurrent Cases of HSV</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/herpes-simplex-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Herpes Simplex Epidemiology</strong></span></a></h2>
<p>In 2023, the prevalence of Herpes Simplex showed distinct trends across the 7MM:</p>
<ul>
<li>There were 13,038 thousand total diagnosed cases of HSV estimated to have occurred in the 7MM in 2023, with approximately 4,948 thousand cases from the US alone. These cases are anticipated to decrease during the study period.</li>
<li>Diagnosed prevalent cases in females were higher than in males across the 7MM, with female-diagnosed cases accounting for 55% of the total cases in the 7MM.</li>
<li>In Japan, 1,555 thousand total diagnosed cases of HSV were estimated in 2023, with 700 thousand male cases and 856 thousand female cases. These cases are also expected to decrease during the study period.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/herpes-simplex-market"><span style="text-decoration: underline;"><strong>Herpes Simplex Market</strong></span></a></h2>
<p>The total market size for Herpes Simplex in the 7MM is approximately USD 3.1 billion in 2023.</p>
<h2>Herpes Simplex Market Drivers</h2>
<ul>
<li>The development of new antiviral treatments, such as PRITELIVIR (AIC-316) and mRNA-1608, provides promising new options for better managing HSV infections and reducing the frequency of outbreaks.</li>
<li>Improved awareness and diagnostic advancements are likely to increase the detection and treatment of symptomatic HSV cases, leading to overall market growth.</li>
</ul>
<h2>Herpes Simplex Market Barriers</h2>
<ul>
<li>The variability in HSV outbreaks and responses to treatment presents a challenge in managing the disease effectively and developing standardized treatments.</li>
<li>Accessibility and affordability of new antiviral treatments may limit widespread adoption, particularly in low-resource regions, creating barriers to market expansion.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/herpes-simplex-pipeline-insight"><span style="text-decoration: underline;"><strong>Herpes Simplex Emerging Therapies</strong></span></a></h2>
<ul>
<li>PRITELIVIR (AIC-316)</li>
<li>GSK3943104</li>
<li>mRNA-1608</li>
</ul>
<p>And others</p>
<h2><strong>Herpes Simplex Key Players</strong></h2>
<ul>
<li>AiCuris Anti-infective Cures AG</li>
<li>GlaxoSmithKline</li>
<li>ModernaTX, Inc.</li>
</ul>
<p>And others</p>

Herpes Simplex Market Infographic

Herpes Simplex Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.